BRAF and neoplasm: Combination BRAF inhibitor plus MEK inhibitor treatment has also been shown to promote the cleavage of gasdermin E and release of HMGB1, suggesting that it may in part regulate the tumour immune microenvironment through pyroptosis (an inflammatory type of programmed cell death) [47].